Clinical Trials Directory

Trials / Completed

CompletedNCT04830371

Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

A Phase II/III, Multicenter, Observer-Blinded, Randomized, Non-inferiority and Safety Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
444 (actual)
Sponsor
EuBiologics Co.,Ltd · Industry
Sex
All
Age
6 Months – 45 Years
Healthy volunteers
Accepted

Summary

This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy Filipino participants aged 6 months to 45 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALEuTCV (Vi-CRM Typhoid conjugate vaccine)Single dose, Intramuscular administration
BIOLOGICALTypbar-TCVSingle dose, Intramuscular administration

Timeline

Start date
2020-09-07
Primary completion
2021-03-18
Completion
2021-08-01
First posted
2021-04-05
Last updated
2021-10-07

Locations

2 sites across 1 country: Philippines

Source: ClinicalTrials.gov record NCT04830371. Inclusion in this directory is not an endorsement.

Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants (NCT04830371) · Clinical Trials Directory